Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.

Proceedings of the National Academy of Sciences of the United States of America - 3 Dec 2019

Tang Shaogeng, Kim Peter S

Abstract excerpt

Immune checkpoint blockade of programmed death-1 (PD-1) by monoclonal antibody drugs has delivered breakthroughs in the treatment of cancer. Nonetheless, small-molecule PD-1 inhibitors could lead to increases in treatment efficacy, safety, and global access. While the ligand-binding surface of apo-PD-1 is relatively flat, it harbors a striking pocket in the murine PD-1/PD-L2 structure. An analogous pocket in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to Allosteric Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amino Acid Substitution

Share to B7-H1 Antigen

Share to Crystallography, X-Ray

Share to Multiprotein Complexes

Share to Programmed Cell Death 1 Receptor

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 31727844
DOI: 10.1073/pnas.1916916116
PMCID: PMC6900541

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.PMID 31727844Read ↗

A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discoverySemantic proximity Read ↗

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2.Semantic proximity Read ↗

Traversing through the Dynamic Protein–Protein Interaction Landscape and Conformational Plasticity of PD-1 for Small-Molecule DiscoverySemantic proximity Read ↗

Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders.Semantic proximity Read ↗

Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian CancerSemantic proximity Read ↗

Virtual Screening and In Vitro Evaluation of PD-1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products.Semantic proximity Read ↗

<i>In silico</i> discovery of pathogenic PD-L1 nsSNVs with aberrant glycosylation and immunotherapy bindingSemantic proximity Read ↗

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small MoleculesSemantic proximity Read ↗

Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1).Semantic proximity Read ↗

Selection of a PD ‐1 blocking antibody from a novel fully human phage display librarySemantic proximity Read ↗

Epitope-Specific Binder Design by Yeast Surface Display.Semantic proximity Read ↗

Human and mouse PD-L1: similar molecular structure, but different druggability profilesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.